Evidence map›Paper›PMID 37504291›Full record

ArticleCurrent issues in molecular biology2023

The Synergistic Antitumor Effect of Decitabine and Vorinostat Combination on HepG2 Human Hepatocellular Carcinoma Cell Line via Epigenetic Modulation of Autophagy-Apoptosis Molecular Crosstalk.

Basant M Salama, Maged W Helmy, Hosny Fouad, Marium M Shamaa, Maha E Houssen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Molecular Pharmacology at the Crossroads of Precision Medicine.Current issues in molecular biology · 2025
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Basant M SalamaDepartment of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour 22511, Egypt.
Maged W HelmyPharmacology and Toxicology Department, Faculty of Pharmacy, Damanhour University, Damanhour 22511, Egypt.ORCID 0000-0003-0375-6762
Hosny FouadPharmacology Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Marium M ShamaaDepartment of Biochemistry, Clinical and Biological Science Division, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria 1029, Egypt.ORCID 0000-0002-3425-0898
Maha E HoussenDepartment of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour 22511, Egypt.
Damanhour University · EGArab Academy for Science, Technology, and Maritime Transport · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a worldwide health issue. Epigenetic alterations play a crucial role in HCC tumorigenesis. Using epigenetic modulators for HCC treatment confers a promising therapeutic effect. The aim of this study was to explore the effect of a decitabine (DAC) and vorinostat (VOR) combination on the crosstalk between apoptosis and autophagy in the HCC HepG2 cell line at 24 h and 72 h. Median inhibitory concentrations (IC

Indexed as

apoptosisautophagydecitabineDNA methyltransferase inhibitorshistone deacetylase inhibitorsvorinostat

Identifiers

PMID37504291
PMCPMC10378248
OpenAlexW4384525498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.